It is currently Sun Nov 23, 2014 5:34 am

News News of Aubagio (teriflunomide)

Site map of Aubagio (teriflunomide) » Forum : Aubagio (teriflunomide)

Aubagio is an oral treatment approved for MS.

Aubagio® delays onset of clinically definite MS, study

Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
Read more : Aubagio® delays onset of clinically definite MS, study | Views : 998 | Replies : 0


Genzyme blitzes Australian MS market with free oral drug

Genzyme blitzes Australian MS market with free oral drug teriflunomide

Image

Drug company Genzyme has launched an aggressive campaign to get its new multiple sclerosis drug teriflunomide prescribed free of charge to patients, in a controversial patient familiarisation program announced the same day the medicine was licensed in Australia.

Each participating neurologist will be able to sign up 10 patients for the once-daily immune system pill, sold under the brand name Aubagio and intended for ...
Read more : Genzyme blitzes Australian MS market with free oral drug | Views : 1701 | Replies : 0


Australian TGA approves Aubagio for relapsing forms of MS

Image

Genzyme, a Sanofi company, has announced that the Australian Therapeutic Goods Administration (TGA) has approved Aubagio® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

The TGA approval will enable health professionals to prescribe Aubagio 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

"We are very pleased with the TGA ...
Read more : Australian TGA approves Aubagio for relapsing forms of MS | Views : 1316 | Replies : 0


Aubagio

Hi. I'm new to the forum, but have been reading posts for a while.

I began taking Aubagio 14mg yesterday. It was a LONG day. Problems: nausea, dizzyness, runny nose, aches like the flu, headache, chills, etc. It seemed the side effects were a lot like Avonex, but not as severe. This morning I feel relatively normal, but will take my second dose in about 30 minutes.

I tried injections with Avonex and Copaxone, but ...
Read more : Aubagio | Views : 16352 | Replies : 45


Aubagio® study confirms significant disability impact

Image

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In the study, once-daily, oral Aubagio® 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in patients with relapsing forms of multiple sclerosis (MS) compared to placebo. In addition, the proportion of patients treated with Aubagio who were relapse-free ...
Read more : Aubagio® study confirms significant disability impact | Views : 1741 | Replies : 0


RE FDA NEWS RELEASE ON NEW DRUG AUBAGIO

http://www.fda.gov/NewsEvents/Newsroom/ ... 319277.htm Please read the nwes release by USFDA on the newdrug aubogio
regards
seeva
Read more : RE FDA NEWS RELEASE ON NEW DRUG AUBAGIO | Views : 2934 | Replies : 0


Oral multiple sclerosis pill Aubagio® gets U.S. approval

Image

Sanofi SA has won U.S. approval for its multiple sclerosis pill Aubagio - one of the two treatments for the chronic disease that could return the French drugmaker to growth after several blockbuster drugs lost patent protection.

The drug has been shown to be less effective than some rivals but has milder side effects and analysts say it could find favour among newly diagnosed patients. Around 35 percent to 40 percent of multiple sclerosis ...
Read more : Oral multiple sclerosis pill Aubagio® gets U.S. approval | Views : 5643 | Replies : 2


Aubagio MS drug by Sanofi

Aubagio, MS drug by Sanofi, is new to me:

http://www.reuters.com/article/2012/06/ ... 8820120601

Positive test boosts Sanofi MS drug hopes
Fri, Jun 1 2012
By Christian Plumb and Elena Berton

PARIS (Reuters) - Sanofi reported positive results from a late-stage trial of its Aubagio multiple sclerosis drug, bolstering its chances of approval by regulators as it seeks to catch up with a fast-selling oral treatment from rival Novartis.

Sanofi said ...
Read more : Aubagio MS drug by Sanofi | Views : 4822 | Replies : 3


Sanofi is looking at new compounds to expand MS business

Image

Sanofi, which bought Genzyme Corp. last year, is seeking new treatments to expand its multiple sclerosis business, said Michael Panzara, Genzyme’s therapeutic area head for multiple sclerosis, immune diseases and neurology.

The drugmaker said today its experimental medicine Lemtrada, which it gained through Genzyme, led to an improvement in disability scores in patients suffering from multiple sclerosis compared with an older treatment in a late-stage trial. The company has another experimental MS therapy, Aubagio, ...
Read more : Sanofi is looking at new compounds to expand MS business | Views : 1697 | Replies : 0


EMA accepts oral MS treatment Teriflunomide marketing app.

EMA accepts oral MS treatment Teriflunomide marketing application

Image

Genzyme, a Sanofi company , announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS). Acceptance of the MAA starts the EMA's review process.

"The filing represents another important milestone for teriflunomide and brings us one step closer to offering a new treatment option to ...
Read more : EMA accepts oral MS treatment Teriflunomide marketing app. | Views : 3585 | Replies : 0


 

Login  •  Register


Statistics

Total posts 221696 • Total topics 23016 • Total members 14540


Contact us | Terms of Service